Squarepoint
RGC icon

Squarepoint’s Regencell Bioscience RGC Stock Holding History

Squarepoint’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$677K Buy
26,613
+602
+2% +$17K ﹤0.01% 3097
2025
Q4 		$546K Sell
26,011
-25,238
-49% -$410K ﹤0.01% 3136
2025
Q3 		$792K Sell
51,249
-48,594
-49% -$697K ﹤0.01% 2872
2025
Q2 		$1.7M Buy
+99,843
New +$1.22M ﹤0.01% 2216

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Squarepoint's RGC Position: Q1 2026 in Review

Squarepoint increased its Regencell Bioscience (RGC) stake by 2.3% in Q1 2026, buying an estimated $17K and bringing the position to 26,613 shares worth $677K. The position accounts for ﹤0.01% of the portfolio, ranked #3097.

Squarepoint first reported a position in RGC in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.7M in Q2 2025. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • Squarepoint held 26,613 shares of Regencell Bioscience worth $677K as of Q1 2026.
  • Squarepoint bought 602 Regencell Bioscience shares in Q1 2026, an estimated $17K.
  • Regencell Bioscience made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3097 holding.
  • Squarepoint first reported a position in Regencell Bioscience in Q2 2025 and has held it in 4 quarters since.
  • Squarepoint's Regencell Bioscience position peaked at $1.7M in Q2 2025.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.